Unexpectedly, hepAGT+/+ mice receiving losartan (10 mg/kg/day) displayed similar body weight gain, fat mass, and liver steatosis severity, as well as the abundance of p-Akt and p-mTOR compared with the mice treated with vehicle (Fig. 6A–G, supplemental Fig. S9). Here, MTOR is linked to fatty liver disease.